PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32598495-4 2020 Strong CYP3A inhibitor use resulted in an 82% increase in the area under the curve (AUC) and a 72% increase in the maximum concentration (Cmax ) of quizartinib. quizartinib 148-159 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 7-12 32598495-10 2020 Only concomitant use of strong CYP3A inhibitors had a clinically meaningful effect on quizartinib and AC886 PK exposure. quizartinib 86-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 31-36 32683457-5 2020 CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and toxicity; therefore dose adjustments (venetoclax, quizartinib, and ivosidenib) or alternative therapies or close monitoring (glasdegib, midostaurin, and gilteritinib) are recommended. quizartinib 185-196 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 32683457-5 2020 CYP3A4 is the main enzyme responsible for SMIs metabolism, and strong CYP3A4 inhibitors, such azoles, could increase drug exposure and toxicity; therefore dose adjustments (venetoclax, quizartinib, and ivosidenib) or alternative therapies or close monitoring (glasdegib, midostaurin, and gilteritinib) are recommended. quizartinib 185-196 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 70-76 33415416-10 2021 Because concomitant strong cytochrome P450 3A (CYP3A) inhibitor use significantly increases quizartinib concentration, these results support the clinical recommendation of quizartinib dose reduction in patients concurrently receiving a strong CYP3A inhibitor. quizartinib 92-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-45 33415416-10 2021 Because concomitant strong cytochrome P450 3A (CYP3A) inhibitor use significantly increases quizartinib concentration, these results support the clinical recommendation of quizartinib dose reduction in patients concurrently receiving a strong CYP3A inhibitor. quizartinib 92-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 33415416-10 2021 Because concomitant strong cytochrome P450 3A (CYP3A) inhibitor use significantly increases quizartinib concentration, these results support the clinical recommendation of quizartinib dose reduction in patients concurrently receiving a strong CYP3A inhibitor. quizartinib 172-183 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 31173645-0 2019 Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. quizartinib 55-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 11-16 31173645-11 2019 CONCLUSIONS: These results suggest reducing the dose of quizartinib when coadministered with a strong CYP3A inhibitor, but not with a moderate or weak CYP3A inhibitor. quizartinib 56-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-107 30898762-6 2019 We found that CYP3A4 plays a major role in BMSC-mediated inhibition in the activity of 3 different FLT3 TKIs (sorafenib, quizartinib, and gilteritinib) against FLT3/ITD acute myeloid leukemia (AML). quizartinib 121-132 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20